Filtered By:
Specialty: Drugs & Pharmacology
Condition: Heart Attack

This page shows you your search results in order of relevance.

Order by Relevance | Date

Total 808 results found since Jan 2013.

Is Sodium Valproate, an HDAC inhibitor, associated with reduced risk of stroke and myocardial infarction? A nested case–control study
ConclusionSodium valproate exposure was associated with the risk of MI, but not ischemic stroke. However, longer exposure to SV was associated with lower odds of stroke, but this might be explained by survivor bias. © 2014 The Authors. Pharmacoepidemiology and Drug Safety published by John Wiley & Sons, Ltd.
Source: Pharmacoepidemiology and Drug Safety - May 1, 2014 Category: Drugs & Pharmacology Authors: Alex Dregan, Judith Charlton, Charles D. A. Wolfe, Martin C. Gulliford, Hugh S. Markus Tags: Original Report Source Type: research

Risks of newly onset hemorrhagic stroke in patients with neovascular age ‐related macular degeneration
ConclusionsPatients with nAMD had a significantly higher risk of developing stroke, which was driven mainly by the increased risk of developing the hemorrhagic subtype.
Source: Pharmacoepidemiology and Drug Safety - August 30, 2017 Category: Drugs & Pharmacology Authors: Wan ‐Ju Annabelle Lee, Ching‐Lan Cheng, Cheng‐Han Lee, Yea‐Huei Kao Yang, Swu‐Jane Lin, Cheng‐Yang Hsieh Tags: ORIGINAL REPORT Source Type: research

Long-term effectiveness and safety of cilostazol versus clopidogrel in secondary prevention of noncardioembolic ischemic stroke
ConclusionsThis real-world study suggests that cilostazol is effective and safe for noncardioembolic ischemic stroke and may be associated with better effectiveness in hypertensive patients compared to clopidogrel.
Source: European Journal of Clinical Pharmacology - June 13, 2023 Category: Drugs & Pharmacology Source Type: research

Antiplatelets in stroke prevention.
Abstract Stroke is the second cause of death worldwide and one of the leading cause of disability. Due to the high rate of recurrence, in high risk-patients (eg patients affected by atherosclerotic vascular disease), long-term antiplatelet therapy reduces the risk of vascular events such as non-fatal myocardial infarction, non-fatal stroke, or vascular death. The percentage of reduction of the events can be estimated in approximately 25%. These data justify the directions that are given to us by the current guidelines for prevention of secondary stroke, which recommend the broad use of antiplatelet therapy both fo...
Source: Current Vascular Pharmacology - January 1, 2014 Category: Drugs & Pharmacology Authors: Pinto A, Di Raimondo D, Tuttolomondo A, Butta C, Licata G Tags: Curr Vasc Pharmacol Source Type: research

Cost-Effectiveness of Apixaban Versus Other New Oral Anticoagulants for Stroke Prevention in Atrial Fibrillation.
CONCLUSIONS: Although our analysis was limited by the absence of head-to-head trials, based on the indirect comparison data available, our model projects that apixaban may be a cost-effective alternative to dabigatran 150 mg BID, dabigatran 110 mg BID, and rivaroxaban 20 mg once daily for stroke prevention in AF patients from the perspective of the United Kingdom National Health Services. PMID: 24508420 [PubMed - as supplied by publisher]
Source: Clinical Therapeutics - February 5, 2014 Category: Drugs & Pharmacology Authors: Lip GY, Kongnakorn T, Phatak H, Kuznik A, Lanitis T, Liu LZ, Iloeje U, Hernandez L, Dorian P Tags: Clin Ther Source Type: research

Prevalence of stroke and myocardial infarction among patients with deteriorated GFR
CONCLUSIONS: Deteriorated GFR <60 mL/min is significantly associated with stroke and myocardial infarction. Stroke and MI are more prevalent among men than women. Stroke and MI are more prevalent in middle-aged adults and older individuals.PMID:36111945 | DOI:10.26355/eurrev_202209_29649
Source: Pharmacological Reviews - September 16, 2022 Category: Drugs & Pharmacology Authors: S H Alharbi Source Type: research